Lupin Launches its Oral Contraceptive Daysee™ Tablets in the US Market;
Generic of Seasonique® Tablets
MUMBAI, India and BALTIMORE, April 12, 2013
MUMBAI, India and BALTIMORE, April 12, 2013 /PRNewswire/ --
Pharma major, Lupin Ltd., announced today that its subsidiary Lupin
Pharmaceuticals Inc. (collectively Lupin) has received final approval for its
Daysee ^™ Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.15
mg/0.03 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg) from the United States
Food and Drugs Administration (US FDA) to market a generic version of Teva
Branded Pharm.'s Seasonique Tablets®. Lupin has already commenced shipping the
Lupin's Daysee ^™ Tablets is indicated for use by women to prevent pregnancy.
Lupin's Daysee ^™ Tablet (Levonorgestrel and Ethinyl estradiol tablets USP
0.15 mg/0.03 mg and Ethinyl estradiol tablets USP 0.01 mg) is available in
Extended-Cycle Wallets each containing a 13-week supply of tablets: 84 light
blue tablets, each containing 0.15 mg of Levonorgestrel and 0.03 mg of Ethinyl
estradiol, and 7 mustard tablets, each containing 0.01 mg of Ethinyl
estradiol. The light blue tablets are round, biconvex, film-coated tablets,
debossed with "LU" on one side and "V21" on the other side. The mustard
tablets are round, biconvex, film-coated tablets debossed with "LU" on one
side and "V22" on the other side.
The total sales for Branded and generic sales for the product stood at USD 161
million (IMS MAT Dec 2012) .
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational
pharmaceutical company producing and developing a wide range of branded and
generic formulations and APIs. The Company is a significant player in the
Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and
NSAID space and holds global leadership positions in the Anti-TB and
Lupin is the 5th largest and fastest growing generics player in the US (5.1%
market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by sales. The Company is also the fastest growing top
10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2012, Lupin's Consolidated Total Income and
Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs.8,676
million (USD 182 million) respectively. Please visit http://www.lupinworld.com
for more information.
Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin
Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is
dedicated to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit http://www.lupinpharmaceuticals.com .
Safe Harbor Statement
For further information or queries please contact - Shamsher Gorawara Head -
Corporate Communications Lupin Limited Ph: +91-98-20-338-555 Email:
Press spacebar to pause and continue. Press esc to stop.